Immunicom

Immunicom is pioneering a disruptive, device-based immunotherapy platform that works outside the body to filter immunosuppressive factors from the blood. Its lead program targets refractory cancers, with initial CE Mark approval in Europe for advanced triple-negative breast cancer and FDA Breakthrough Device designation. The company is advancing a global clinical trial strategy across multiple oncology indications and exploring applications in autoimmune and inflammatory diseases, positioning its technology as a potential backbone for combination therapies.

Immunopheresis™: An extracorporeal blood filtration platform that uses single-use cartridges with affinity ligands to selectively remove specific immunosuppressive or pathogenic proteins (e.g., soluble checkpoint proteins, cytokines) from a patient's blood, aiming to restore natural immune function.

Immunicom competes in the broad immunotherapy space but with a unique, device-based subtractive mechanism. Direct competitors are few, but it faces indirect competition from all systemic cancer immunotherapies (checkpoint inhibitors, bispecifics, cell therapies) and companies developing other extracorporeal immunomodulation technologies. Its success hinges on demonstrating clinical superiority or complementary efficacy.